Anzeige
Erschienen in:
01.09.2015 | Hepatitisviren | Klinische Studien
Schritt für Schritt zur perfekten Hepatitis-C-Therapie für alle Genotypen
Erschienen in: Die Innere Medizin | Ausgabe 9/2015
Einloggen, um Zugang zu erhaltenAuszug
-
Lawitz E, Gane E, Pearlman B et al. (2015) Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385:1075–1086
-
Sulkowski M, Hezode C, Gerstoft J et al. (2015) Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385:1087–1097
-
Molina JM, Orkin C, Iser DM et al. (2015) Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 385:1098–1106
-
Hézode C, Asselah T, Reddy KR et al. (2015) Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385:2502–2509